Biondo Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.5M | Sell |
25,145
-170
| -0.7% | -$75.3K | 1.53% | 21 |
|
|
2026
Q1 | $11.3M | Buy |
25,315
+175
| +0.7% | +$81.6K | 1.45% | 29 |
|
|
2025
Q4 | $11.4M | Buy |
25,140
+65
| +0.3% | +$28K | 1.38% | 27 |
|
|
2025
Q3 | $9.82M | Buy |
25,075
+146
| +0.6% | +$61K | 1.23% | 32 |
|
|
2025
Q2 | $11.1M | Sell |
24,929
-220
| -0.9% | -$101K | 1.46% | 24 |
|
|
2025
Q1 | $12.2M | Sell |
25,149
-131
| -0.5% | -$61K | 1.73% | 21 |
|
|
2024
Q4 | $10.2M | Buy |
25,280
+185
| +0.7% | +$85.8K | 1.4% | 26 |
|
|
2024
Q3 | $11.7M | Buy |
25,095
+665
| +3% | +$319K | 1.6% | 23 |
|
|
2024
Q2 | $11.5M | Buy |
24,430
+23,765
| +3,574% | +$10.3M | 1.7% | 17 |
|
|
2024
Q1 | $278K | Hold |
665
| – | – | 0.04% | 83 |
|
|
2023
Q4 | $271K | Hold |
665
| – | – | 0.05% | 71 |
|
|
2023
Q3 | $231K | Sell |
665
-100
| -13% | -$35K | 0.04% | 77 |
|
|
2023
Q2 | $269K | Hold |
765
| – | – | 0.05% | 73 |
|
|
2023
Q1 | $241K | Buy |
+765
| New | +$229K | 0.05% | 73 |
|
|
2021
Q2 | – | Sell |
-32,026
| Closed | -$6.88M | – | 88 |
|
|
2021
Q1 | $6.88M | Sell |
32,026
-37,342
| -54% | -$8.2M | 1.37% | 23 |
|
|
2020
Q4 | $16.4M | Buy |
69,368
+5,430
| +8% | +$1.25M | 3.14% | 8 |
|
|
2020
Q3 | $17.4M | Sell |
63,938
-915
| -1% | -$252K | 3.77% | 7 |
|
|
2020
Q2 | $18.8M | Sell |
64,853
-265
| -0.4% | -$71.8K | 4.75% | 5 |
|
|
2020
Q1 | $15.5M | Sell |
65,118
-1,552
| -2% | -$356K | 5.13% | 4 |
|
|
2019
Q4 | $14.6M | Buy |
66,670
+15,040
| +29% | +$3.04M | 3.37% | 8 |
|
|
2019
Q3 | $8.75M | Sell |
51,630
-4,220
| -8% | -$747K | 2.24% | 13 |
|
|
2019
Q2 | $10.2M | Buy |
55,850
+900
| +2% | +$157K | 2.43% | 10 |
|
|
2019
Q1 | $10.1M | Buy |
54,950
+8,930
| +19% | +$1.65M | 2.54% | 11 |
|
|
2018
Q4 | $7.63M | Buy |
46,020
+3,715
| +9% | +$644K | 2.3% | 12 |
|
|
2018
Q3 | $8.15M | Buy |
42,305
+7,785
| +23% | +$1.39M | 1.94% | 14 |
|
|
2018
Q2 | $5.87M | Buy |
34,520
+545
| +2% | +$84.5K | 1.48% | 20 |
|
|
2018
Q1 | $5.54M | Buy |
33,975
+4,720
| +16% | +$771K | 1.44% | 24 |
|
|
2017
Q4 | $4.38M | Buy |
29,255
+180
| +0.6% | +$26.7K | 1.11% | 30 |
|
|
2017
Q3 | $4.42M | Buy |
29,075
+26,075
| +869% | +$3.92M | 1.22% | 25 |
|
|
2017
Q2 | $387K | Buy |
+3,000
| New | +$361K | 0.11% | 69 |
|
|
2016
Q4 | – | Sell |
-43,612
| Closed | -$3.8M | – | 80 |
|
|
2016
Q3 | $3.8M | Buy |
+43,612
| New | +$4.12M | 1.29% | 27 |
|
Other funds holding VRTX
Biondo Investment Advisors's VRTX Position: Q2 2026 in Review
Biondo Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.67% in Q2 2026, selling an estimated $75.3K and leaving 25,145 shares worth $12.5M. The position accounts for 1.53% of the portfolio, ranked #21.
Biondo Investment Advisors first reported a position in VRTX in Q3 2016 and has held it in 31 quarters since. The position peaked at $18.8M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Biondo Investment Advisors held 25,145 shares of Vertex Pharmaceuticals worth $12.5M as of Q2 2026.
- Biondo Investment Advisors sold 170 Vertex Pharmaceuticals shares in Q2 2026, an estimated $75.3K.
- Vertex Pharmaceuticals made up 1.53% of Biondo Investment Advisors's portfolio in Q2 2026, its #21 holding.
- Biondo Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 31 quarters since.
- Biondo Investment Advisors's Vertex Pharmaceuticals position peaked at $18.8M in Q2 2020.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Biondo Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.